Free Trial
NASDAQ:VTYX

Ventyx Biosciences Q1 2025 Earnings Report

Ventyx Biosciences logo
$1.07 +0.01 (+0.94%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$1.07 0.00 (0.00%)
As of 04/17/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ventyx Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.48
Beat/Miss
N/A
One Year Ago EPS
N/A

Ventyx Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ventyx Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Ventyx Biosciences Earnings Headlines

Ventyx Biosciences announces seven additional appointments to SAB
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)
See More Ventyx Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ventyx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ventyx Biosciences and other key companies, straight to your email.

About Ventyx Biosciences

Ventyx Biosciences (NASDAQ:VTYX), a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

View Ventyx Biosciences Profile

More Earnings Resources from MarketBeat